SBHMY (Sino Biopharmaceutical) 3-Year EBITDA Growth Rate : -2.30% (As of Jun. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Sino Biopharmaceutical 3-Year EBITDA Growth Rate?

Sino Biopharmaceutical's EBITDA per Share for the six months ended in Jun. 2024 was $0.56.

During the past 12 months, Sino Biopharmaceutical's average EBITDA Per Share Growth Rate was 24.10% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -2.30% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -6.80% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 14.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Sino Biopharmaceutical was 61.30% per year. The lowest was -39.00% per year. And the median was 20.25% per year.

Competitive Comparison of Sino Biopharmaceutical's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Sino Biopharmaceutical's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sino Biopharmaceutical's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Sino Biopharmaceutical's 3-Year EBITDA Growth Rate falls into.

Save Embed

;

Save Embed

;

Sino Biopharmaceutical 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Sino Biopharmaceutical (OTCPK:SBHMY) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Sino Biopharmaceutical 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Sino Biopharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (OTCPK:SBHMY) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

SBMFF:USA 01177:Hong Kong SMZ1:Germany

Address

1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG

Website

https://www.sinobiopharm.com

Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2023, 37.8% of the firm's total revenue comes from five innovative drugs and five biosimilar drugs. Sino Biopharm's biggest revenue segment is oncology medicines, accounting for 33.6% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.